Literature DB >> 21289111

Interaction of Kaposi's sarcoma-associated herpesvirus ORF59 with oriLyt is dependent on binding with K-Rta.

Cyprian C Rossetto1, Ni Ketut Susilarini, Gregory S Pari.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) displays two distinct life stages, latency and lytic reactivation. Progression through the lytic cycle and replication of the viral genome constitute an essential step toward the production of infectious virus and human disease. KSHV K-RTA has been shown to be the major transactivator required for the initiation of lytic reactivation. In the transient-cotransfection replication assay, K-Rta is the only noncore protein required for DNA synthesis. K-Rta was shown to interact with both C/EBPα binding motifs and the R response elements (RRE) within oriLyt. It is postulated that K-Rta acts in part to facilitate the recruitment of replication factors to oriLyt. In order to define the role of K-Rta in the initiation of lytic DNA synthesis, we show an interaction with ORF59, the DNA polymerase processivity factor (PF), one of the eight virally encoded proteins necessary for origin-dependent DNA replication. Using the chromatin immunoprecipitation (ChIP) assay, both K-Rta and ORF59 interact with the RRE and C/EBPα binding motifs within oriLyt in cells harboring the KSHV bacterial artificial chromosome (BAC). A transient-transfection ChIP assay demonstrated that the interaction of ORF59 with oriLyt is dependent on binding with K-Rta and that ORF59 fails to bind to oriLyt in the absence of K-Rta. Also, using the cotransfection replication assay, overexpression of the interaction domain of K-Rta with ORF59 has a dominant negative effect on oriLyt amplification, suggesting that the interaction of K-Rta with ORF59 is essential for DNA synthesis and supporting the hypothesis that K-Rta facilitates the formation of a replication complex at oriLyt.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289111      PMCID: PMC3126130          DOI: 10.1128/JVI.02361-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Human Kaposi's sarcoma herpesvirus processivity factor-8 functions as a dimer in DNA synthesis.

Authors:  Xulin Chen; Kai Lin; Robert P Ricciardi
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

2.  Amplification of the Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 lytic origin of DNA replication is dependent upon a cis-acting AT-rich region and an ORF50 response element and the trans-acting factors ORF50 (K-Rta) and K8 (K-bZIP).

Authors:  David P AuCoin; Kelly S Colletti; Sylvia A Cei; Iva Papousková; Margaret Tarrant; Gregory S Pari
Journal:  Virology       Date:  2004-01-20       Impact factor: 3.616

3.  The Epstein-Barr virus (EBV) DNA polymerase accessory protein, BMRF1, activates the essential downstream component of the EBV oriLyt.

Authors:  Q Zhang; E Holley-Guthrie; J Q Ge; D Dorsky; S Kenney
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

4.  Herpes simplex virus DNA replication: the UL9 gene encodes an origin-binding protein.

Authors:  P D Olivo; N J Nelson; M D Challberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

5.  Characterization of human herpesvirus 8 ORF59 protein (PF-8) and mapping of the processivity and viral DNA polymerase-interacting domains.

Authors:  S R Chan; B Chandran
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus lytic origin (ori-Lyt)-dependent DNA replication: identification of the ori-Lyt and association of K8 bZip protein with the origin.

Authors:  Cui Li Lin; Hong Li; Yan Wang; Fan Xiu Zhu; Sagar Kudchodkar; Yan Yuan
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Origin-specific unwinding of herpes simplex virus 1 DNA by the viral UL9 and ICP8 proteins: visualization of a specific preunwinding complex.

Authors:  Alexander M Makhov; Sam S-K Lee; I Robert Lehman; Jack D Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

8.  Helicase motif Ia is involved in single-strand DNA-binding and helicase activities of the herpes simplex virus type 1 origin-binding protein, UL9.

Authors:  Boriana Marintcheva; Sandra K Weller
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Human cytomegalovirus UL84 oligomerization and heterodimerization domains act as transdominant inhibitors of oriLyt-dependent DNA replication: evidence that IE2-UL84 and UL84-UL84 interactions are required for lytic DNA replication.

Authors:  Kelly S Colletti; Yiyang Xu; Sylvia A Cei; Margaret Tarrant; Gregory S Pari
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Functional interaction between the herpes simplex virus type 1 polymerase processivity factor and origin-binding proteins: enhancement of UL9 helicase activity.

Authors:  Kelly S Trego; Deborah S Parris
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  18 in total

1.  Kaposi's sarcoma-associated herpesvirus noncoding polyadenylated nuclear RNA interacts with virus- and host cell-encoded proteins and suppresses expression of genes involved in immune modulation.

Authors:  Cyprian C Rossetto; Gregory S Pari
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells.

Authors:  Adriana Forero; Patrick S Moore; Saumendra N Sarkar
Journal:  J Immunol       Date:  2013-06-26       Impact factor: 5.422

3.  The cellular peptidyl-prolyl cis/trans isomerase Pin1 regulates reactivation of Kaposi's sarcoma-associated herpesvirus from latency.

Authors:  Jonathan Guito; Aileen Gavina; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

4.  Downregulation of Poly(ADP-Ribose) Polymerase 1 by a Viral Processivity Factor Facilitates Lytic Replication of Gammaherpesvirus.

Authors:  Woo-Chang Chung; Joo-Hee Park; Hye-Ri Kang; Moon Jung Song
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

5.  Kaposi's sarcoma-associated herpesvirus Rta tetramers make high-affinity interactions with repetitive DNA elements in the Mta promoter to stimulate DNA binding of RBP-Jk/CSL.

Authors:  Diana Palmeri; Kyla Driscoll Carroll; Olga Gonzalez-Lopez; David M Lukac
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

6.  Phosphorylation of Kaposi's sarcoma-associated herpesvirus processivity factor ORF59 by a viral kinase modulates its ability to associate with RTA and oriLyt.

Authors:  Maria E McDowell; Pravinkumar Purushothaman; Cyprian C Rossetto; Gregory S Pari; Subhash C Verma
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

7.  Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells.

Authors:  Cyprian C Rossetto; Margaret Tarrant-Elorza; Gregory S Pari
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

8.  Multiple regions of Kaposi's sarcoma-associated herpesvirus ORF59 RNA are required for its expression mediated by viral ORF57 and cellular RBM15.

Authors:  Maria Julia Massimelli; Vladimir Majerciak; Jeong-Gu Kang; David J Liewehr; Seth M Steinberg; Zhi-Ming Zheng
Journal:  Viruses       Date:  2015-02-03       Impact factor: 5.048

Review 9.  PAN's Labyrinth: Molecular biology of Kaposi's sarcoma-associated herpesvirus (KSHV) PAN RNA, a multifunctional long noncoding RNA.

Authors:  Cyprian C Rossetto; Gregory S Pari
Journal:  Viruses       Date:  2014-11-04       Impact factor: 5.048

10.  Abortive lytic reactivation of KSHV in CBF1/CSL deficient human B cell lines.

Authors:  Barbara A Scholz; Marie L Harth-Hertle; Georg Malterer; Juergen Haas; Joachim Ellwart; Thomas F Schulz; Bettina Kempkes
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.